Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Pantoprazole does not reduce upper gastrointestinal bleeding during anticoagulation treatment

07 Aug 2019

Proton pump inhibitor therapy, particularly with pantoprazole, does not reduce upper gastrointestinal bleeding events in patients taking low-dose anticoagulation/aspirin treatment, reports a recent study.

Researchers randomly assigned 17,598 patients with stable cardiovascular and peripheral artery disease to receive either daily 40-mg pantoprazole (n=8,791; mean age, 67.6±8.1 years; 22 percent female) or placebo (n=8,807; mean age, 67.7±8.1 years; 21 percent female). Participants were also given rivaroxaban 2.5 mg twice daily with 100-mg aspirin once daily, rivaroxaban 5 mg twice daily or aspirin 100 mg alone.

The primary efficacy outcome of clinically significant events in the upper gastrointestinal tract occurred in 1.2 percent (n=102) of the pantoprazole arm and in 1.3 percent (n=116) of the placebo group. The difference did not reach significance (hazard ratio [HR], 0.88, 95 percent CI, 0.67–1.15).

Further analysis according to the components of upper gastrointestinal bleeding showed that both treatment arms were comparable in terms of overt or occult bleeding events. However, the likelihood of gastroduodenal bleeding was significantly attenuated in patients who were given pantoprazole (HR, 0.52, 0.28–0.94; p=0.03).

In a subsequent posthoc analysis where the definition of bleeding events was broadened, pantoprazole use remained significantly associated with a lower risk of bleeding of gastroduodenal lesions (HR, 0.45, 0.27–0.74). Pantoprazole also exerted a significant protective effect against peptic ulcer (HR, 0.46, 0.25–0.83) and erosions (HR, 0.13–0.84).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.